Literature DB >> 12424936

Examination, prevention and treatment of osteoporosis in patients with inflammatory bowel disease: recommendations and reality.

A Kirchgatterer1, H H Wenzl, G Aschl, M Hinterreiter, B Stadler, T A Hinterleitner, W Petritsch, P Knoflach.   

Abstract

BACKGROUND: Patients with inflammatory bowel disease (IBD) are at increased risk of developing osteopenia and osteoporosis. Our aim was to evaluate the current practices of examination, prevention and treatment of osteoporosis in IBD patients in a routine clinical setting.
METHODS: A total of 154 consecutive patients with IBD (63 female, 91 male; 36 ulcerative colitis, 115 Crohn's disease, 3 indeterminate colitis), referred to two gastroenterological units for scheduled follow-up examinations, were included. Patient charts were evaluated regarding bone densitometry already performed and any prophylactic or therapeutic interventions in cases of low bone mineral density.
RESULTS: Bone mineral density (BMD) measurements had been performed only in 38 patients (25%). BMD was abnormally low in 27 of the examined patients (71%), 20 of whom had osteopenia and seven had osteoporosis. Among the subgroup of patients on long-term steroid therapy (77 patients), 30 had been referred to bone densitometry during the course of disease, and 21 of them were found to have low bone mineral density. Preventive measures were prescribed in 12 patients (9% of the whole study population). In the majority of the patients with low bone mineral density, calcium and vitamin D were used as treatment.
CONCLUSIONS: Despite the high prevalence of osteopenia and osteoporosis in patients with IBD, only a minority of these patients were included in a structured program in accordance with modern guidelines for diagnosing and preventing this extraintestinal complication in a routine clinical setting.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12424936     DOI: 10.1046/j.1563-2571.2002.02018.x

Source DB:  PubMed          Journal:  Acta Med Austriaca        ISSN: 0303-8173


  5 in total

1.  Guideline recommendations for treatment of patients with inflammatory bowel diseases are not implemented in clinical practice-results of a non-representative survey.

Authors:  Lea I Kredel; Oliver Schneidereit; Jörg C Hoffmann; Britta Siegmund; Jan C Preiß
Journal:  Int J Colorectal Dis       Date:  2018-12-07       Impact factor: 2.571

2.  The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss.

Authors:  A R Moschen; A Kaser; B Enrich; O Ludwiczek; M Gabriel; P Obrist; A M Wolf; H Tilg
Journal:  Gut       Date:  2005-04       Impact factor: 23.059

3.  Treatment of Extraintestinal Manifestations in Inflammatory Bowel Disease.

Authors:  Adrian A. Van Bodegraven; A. Salvador Peña
Journal:  Curr Treat Options Gastroenterol       Date:  2003-06

Review 4.  Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures.

Authors:  N C W Harvey; E V McCloskey; P J Mitchell; B Dawson-Hughes; D D Pierroz; J-Y Reginster; R Rizzoli; C Cooper; J A Kanis
Journal:  Osteoporos Int       Date:  2017-02-07       Impact factor: 4.507

5.  Correlation between low bone density and disease activity in patients with ulcerative colitis.

Authors:  Taghi Amiriani; Sima Besharat; Zahra Pourramezan; Honey Sadat Mirkarimi; Mehrdad Aghaei; Hamidreza Joshaghani; Gholamreza Roshandel; Maryam Faghani; Mahsa Besharat
Journal:  Middle East J Dig Dis       Date:  2015-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.